FAP and cancer: Haberkorn’s group reported a series of piperazine-based FAP-inhibitors labelled with the positron emitter gallium-68, which were successfully used for imaging various cancers [3,4], particularly when utilizing the most prominent molecules among their structures such as FAPI-04, FAPI-21, and FAPI-46 [4].